Search

EHA-Baltic Hematology Tutorial on Lymphoid Malignancies, including Waldenström's Macroglobulinemia

EHA in close collaboration with the Estonian Society of Haematology, the Lithuanian Society of Hematology and the Latvian Hematology Society are organizing the first EHA-Baltic Hematology Tutorial on Lymphoid Malignancies, including Waldenström's Macroglobulinemia.

Read more

Immunoglobulin shortages in the spotlight: EMA, SUPPLY and the SoHO Regulation

EMA executive director Emer Cooke welcoming participants including EHA at the Shortages Workshop, March 1

 

Shortages of immunoglobulins and the need to increase and sustain plasma supplies have moved to the center of the EU policy and regulatory stage.

Read more

Nikolai Klimko 1956-2023

Professor Nikolai Klimko 

Professor Nikolai Klimko, MD PhD, FECMM
March 22, 1956 - March 30, 2023

With deepest sorrow we learned that on March 30, 2023, Professor Nikolai Nikolaevich Klimko passed at age 68.

Read more

Clinical trials

The advance of highly innovative, increasingly personalized therapies in hematology requires novel clinical trial designs and more flexible, adaptive regulatory frameworks and improved data generation to support decision making both during and after clinical studies.

Read more

About us

The European Hematology Association (EHA): “Towards prevention, cure, and quality of life for all patients with blood disorders”.

Read more

Addressing immunoglobulin shortages: EHA and EBA’s strategic recommendations at the EMA

In recent years, shortages of immunoglobulins (Ig) have become a growing concern in the European Union (EU). Since 2018, the European Medicines Agency (EMA)—the EU agency that evaluates and supervises medicines—has received an increasing number of shortage reports.

Read more

IVDR

As of May 26, 2022, the new EU In Vitro Diagnostic medical devices Regulation (IVDR) comes into effect.

Read more

Treatment and survival of patients with chronic myeloid leukemia (CML) in Europe

Since the introduction of tyrosine kinase inhibitors into the treatment of CML survival times have greatly improved.

Read more